10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024

Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022 PLEASANTON, Calif., Feb. 15, 2024 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks